1. Home
  2. CTMX vs CUE Comparison

CTMX vs CUE Comparison

Compare CTMX & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTMX
  • CUE
  • Stock Information
  • Founded
  • CTMX 2008
  • CUE 2014
  • Country
  • CTMX United States
  • CUE United States
  • Employees
  • CTMX N/A
  • CUE N/A
  • Industry
  • CTMX Biotechnology: Pharmaceutical Preparations
  • CUE Biotechnology: Pharmaceutical Preparations
  • Sector
  • CTMX Health Care
  • CUE Health Care
  • Exchange
  • CTMX Nasdaq
  • CUE Nasdaq
  • Market Cap
  • CTMX 62.3M
  • CUE 91.9M
  • IPO Year
  • CTMX 2015
  • CUE 2018
  • Fundamental
  • Price
  • CTMX $0.80
  • CUE $1.49
  • Analyst Decision
  • CTMX Buy
  • CUE Strong Buy
  • Analyst Count
  • CTMX 6
  • CUE 5
  • Target Price
  • CTMX $5.77
  • CUE $5.00
  • AVG Volume (30 Days)
  • CTMX 731.5K
  • CUE 254.0K
  • Earning Date
  • CTMX 03-10-2025
  • CUE 03-10-2025
  • Dividend Yield
  • CTMX N/A
  • CUE N/A
  • EPS Growth
  • CTMX N/A
  • CUE N/A
  • EPS
  • CTMX 0.16
  • CUE N/A
  • Revenue
  • CTMX $126,617,000.00
  • CUE $9,532,000.00
  • Revenue This Year
  • CTMX $22.55
  • CUE $73.11
  • Revenue Next Year
  • CTMX N/A
  • CUE $11.02
  • P/E Ratio
  • CTMX $4.93
  • CUE N/A
  • Revenue Growth
  • CTMX 33.66
  • CUE 149.53
  • 52 Week Low
  • CTMX $0.75
  • CUE $0.45
  • 52 Week High
  • CTMX $5.85
  • CUE $2.37
  • Technical
  • Relative Strength Index (RSI)
  • CTMX 41.61
  • CUE 58.61
  • Support Level
  • CTMX $0.75
  • CUE $1.22
  • Resistance Level
  • CTMX $0.98
  • CUE $1.50
  • Average True Range (ATR)
  • CTMX 0.06
  • CUE 0.12
  • MACD
  • CTMX 0.00
  • CUE 0.00
  • Stochastic Oscillator
  • CTMX 20.13
  • CUE 96.67

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Share on Social Networks: